Afuco™ Anti-Human CXCL13 ADCC Therapeutic Antibody (VX5), ADCC Enhanced
Anti-CXCL13 ADCC Enhanced Antibody (VX5) is an ADCC enhanced antibody produced by our Afuco™ platform. VX5 is a monoclonal antibody that specifically binds human, primate and rodent CXCL13, neutralizes its activity and exhibits therapeutic benefit in mouse models of human autoimmune diseases (such as rheumatoid arthritis and multiple sclerosis).
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-190CL |
| Pricing | Inquiry |
| Host | Human |
| Target | CXCL13 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Storage | 4°C or -20°C, avoid repeated freezing and thawing. |